{"id":996169,"date":"2026-08-17T16:04:12","date_gmt":"2026-08-17T20:04:12","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/amylyx-pharmaceuticals-to-announce-topline-results-from-its-phase-3-lucidity-clinical-trial-of-avexitide-in-post-bariatric-hypoglycemia-on-august-18-2026\/"},"modified":"2026-08-17T16:04:12","modified_gmt":"2026-08-17T20:04:12","slug":"amylyx-pharmaceuticals-to-announce-topline-results-from-its-phase-3-lucidity-clinical-trial-of-avexitide-in-post-bariatric-hypoglycemia-on-august-18-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/amylyx-pharmaceuticals-to-announce-topline-results-from-its-phase-3-lucidity-clinical-trial-of-avexitide-in-post-bariatric-hypoglycemia-on-august-18-2026\/","title":{"rendered":"Amylyx Pharmaceuticals to Announce Topline Results from its Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia on August 18, 2026"},"content":{"rendered":"

<\/p>\n

Amylyx Pharmaceuticals to Announce Topline Results from its Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia on August 18, 2026<\/b><\/p>\n

CAMBRIDGE, Mass.–(BUSINESS WIRE<\/a>)–Amylyx Pharmaceuticals, Inc.<\/a> (Nasdaq: AMLX) (\u201cAmylyx\u201d or the \u201cCompany\u201d) will announce topline results from its Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia on August 18, 2026. Amylyx\u2019s senior management team will host a conference call and audio webcast at 8:00 a.m. ET.<\/p>\n

\nTo access the conference call, please dial +1 (888) 880-3330 (U.S. & Canada) or +1 (646) 357-8766 (international) at least 10 minutes prior to the start time and ask to be joined into the Amylyx Pharmaceuticals call. A live audio webcast of the call will be available under \u201cEvents and Presentations\u201d in the Investor section of the Company\u2019s website, https:\/\/investors.amylyx.com\/events-presentations<\/a>. The webcast will be archived and available for replay for 90 days following the event.<\/p>\n

About Amylyx Pharmaceuticals<\/strong><\/p>\n

\nAt Amylyx, our mission is to usher in a new era of treating diseases with high unmet needs. Where others see challenges, we see opportunities that we pursue with urgency, rigorous science, and unwavering commitment to the communities we serve. We are currently focused on four investigational therapies across several endocrine conditions and neurodegenerative diseases in which we believe can make the greatest impact. For more information, visit amylyx.com<\/a> and follow us on LinkedIn<\/a> and X<\/a>. For investors, please visit investors.amylyx.com<\/a>.<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20260817660841\/en\/<\/a><\/span><\/p>\n

Media
\n<\/strong>
Amylyx Media Team
\n
+1 (857) 320-6191
\n
amylyxmediateam@amylyx.com
\n<\/a><\/p>\n

Investors
\n<\/strong>
Lindsey Allen
\n
Amylyx Pharmaceuticals, Inc.
\n
+1 (857) 320-6244
\n
Investors@amylyx.com<\/a><\/p>\n

KEYWORDS:<\/b> Massachusetts United States North America<\/p>\n

INDUSTRY KEYWORDS:<\/b> Health Clinical Trials Research Pharmaceutical Science Biotechnology<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Amylyx Pharmaceuticals to Announce Topline Results from its Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia on August 18, 2026 CAMBRIDGE, Mass.–(BUSINESS WIRE)–Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (\u201cAmylyx\u201d or the \u201cCompany\u201d) will announce topline results from its Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia on August 18, 2026. Amylyx\u2019s senior management team will host a conference call and audio webcast at 8:00 a.m. ET. To access the conference call, please dial +1 (888) 880-3330 (U.S. & Canada) or +1 (646) 357-8766 (international) at least 10 minutes prior to the start time and ask to be joined into the Amylyx Pharmaceuticals call. A live audio webcast of the call will be available under \u201cEvents and Presentations\u201d … <\/p>\n

Continue reading “Amylyx Pharmaceuticals to Announce Topline Results from its Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia on August 18, 2026”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-996169","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAmylyx Pharmaceuticals to Announce Topline Results from its Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia on August 18, 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/amylyx-pharmaceuticals-to-announce-topline-results-from-its-phase-3-lucidity-clinical-trial-of-avexitide-in-post-bariatric-hypoglycemia-on-august-18-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Amylyx Pharmaceuticals to Announce Topline Results from its Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia on August 18, 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Amylyx Pharmaceuticals to Announce Topline Results from its Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia on August 18, 2026 CAMBRIDGE, Mass.–(BUSINESS WIRE)–Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (\u201cAmylyx\u201d or the \u201cCompany\u201d) will announce topline results from its Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia on August 18, 2026. Amylyx\u2019s senior management team will host a conference call and audio webcast at 8:00 a.m. ET. To access the conference call, please dial +1 (888) 880-3330 (U.S. & Canada) or +1 (646) 357-8766 (international) at least 10 minutes prior to the start time and ask to be joined into the Amylyx Pharmaceuticals call. A live audio webcast of the call will be available under \u201cEvents and Presentations\u201d … Continue reading "Amylyx Pharmaceuticals to Announce Topline Results from its Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia on August 18, 2026"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/amylyx-pharmaceuticals-to-announce-topline-results-from-its-phase-3-lucidity-clinical-trial-of-avexitide-in-post-bariatric-hypoglycemia-on-august-18-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-17T20:04:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260817660841r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amylyx-pharmaceuticals-to-announce-topline-results-from-its-phase-3-lucidity-clinical-trial-of-avexitide-in-post-bariatric-hypoglycemia-on-august-18-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amylyx-pharmaceuticals-to-announce-topline-results-from-its-phase-3-lucidity-clinical-trial-of-avexitide-in-post-bariatric-hypoglycemia-on-august-18-2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Amylyx Pharmaceuticals to Announce Topline Results from its Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia on August 18, 2026\",\"datePublished\":\"2026-08-17T20:04:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amylyx-pharmaceuticals-to-announce-topline-results-from-its-phase-3-lucidity-clinical-trial-of-avexitide-in-post-bariatric-hypoglycemia-on-august-18-2026\\\/\"},\"wordCount\":296,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amylyx-pharmaceuticals-to-announce-topline-results-from-its-phase-3-lucidity-clinical-trial-of-avexitide-in-post-bariatric-hypoglycemia-on-august-18-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260817660841r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amylyx-pharmaceuticals-to-announce-topline-results-from-its-phase-3-lucidity-clinical-trial-of-avexitide-in-post-bariatric-hypoglycemia-on-august-18-2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amylyx-pharmaceuticals-to-announce-topline-results-from-its-phase-3-lucidity-clinical-trial-of-avexitide-in-post-bariatric-hypoglycemia-on-august-18-2026\\\/\",\"name\":\"Amylyx Pharmaceuticals to Announce Topline Results from its Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia on August 18, 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amylyx-pharmaceuticals-to-announce-topline-results-from-its-phase-3-lucidity-clinical-trial-of-avexitide-in-post-bariatric-hypoglycemia-on-august-18-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amylyx-pharmaceuticals-to-announce-topline-results-from-its-phase-3-lucidity-clinical-trial-of-avexitide-in-post-bariatric-hypoglycemia-on-august-18-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260817660841r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2026-08-17T20:04:12+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amylyx-pharmaceuticals-to-announce-topline-results-from-its-phase-3-lucidity-clinical-trial-of-avexitide-in-post-bariatric-hypoglycemia-on-august-18-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amylyx-pharmaceuticals-to-announce-topline-results-from-its-phase-3-lucidity-clinical-trial-of-avexitide-in-post-bariatric-hypoglycemia-on-august-18-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amylyx-pharmaceuticals-to-announce-topline-results-from-its-phase-3-lucidity-clinical-trial-of-avexitide-in-post-bariatric-hypoglycemia-on-august-18-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260817660841r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260817660841r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amylyx-pharmaceuticals-to-announce-topline-results-from-its-phase-3-lucidity-clinical-trial-of-avexitide-in-post-bariatric-hypoglycemia-on-august-18-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Amylyx Pharmaceuticals to Announce Topline Results from its Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia on August 18, 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Amylyx Pharmaceuticals to Announce Topline Results from its Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia on August 18, 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/amylyx-pharmaceuticals-to-announce-topline-results-from-its-phase-3-lucidity-clinical-trial-of-avexitide-in-post-bariatric-hypoglycemia-on-august-18-2026\/","og_locale":"en_US","og_type":"article","og_title":"Amylyx Pharmaceuticals to Announce Topline Results from its Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia on August 18, 2026 - Market Newsdesk","og_description":"Amylyx Pharmaceuticals to Announce Topline Results from its Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia on August 18, 2026 CAMBRIDGE, Mass.–(BUSINESS WIRE)–Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (\u201cAmylyx\u201d or the \u201cCompany\u201d) will announce topline results from its Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia on August 18, 2026. Amylyx\u2019s senior management team will host a conference call and audio webcast at 8:00 a.m. ET. To access the conference call, please dial +1 (888) 880-3330 (U.S. & Canada) or +1 (646) 357-8766 (international) at least 10 minutes prior to the start time and ask to be joined into the Amylyx Pharmaceuticals call. A live audio webcast of the call will be available under \u201cEvents and Presentations\u201d … Continue reading \"Amylyx Pharmaceuticals to Announce Topline Results from its Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia on August 18, 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/amylyx-pharmaceuticals-to-announce-topline-results-from-its-phase-3-lucidity-clinical-trial-of-avexitide-in-post-bariatric-hypoglycemia-on-august-18-2026\/","og_site_name":"Market Newsdesk","article_published_time":"2026-08-17T20:04:12+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260817660841r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/amylyx-pharmaceuticals-to-announce-topline-results-from-its-phase-3-lucidity-clinical-trial-of-avexitide-in-post-bariatric-hypoglycemia-on-august-18-2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/amylyx-pharmaceuticals-to-announce-topline-results-from-its-phase-3-lucidity-clinical-trial-of-avexitide-in-post-bariatric-hypoglycemia-on-august-18-2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Amylyx Pharmaceuticals to Announce Topline Results from its Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia on August 18, 2026","datePublished":"2026-08-17T20:04:12+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/amylyx-pharmaceuticals-to-announce-topline-results-from-its-phase-3-lucidity-clinical-trial-of-avexitide-in-post-bariatric-hypoglycemia-on-august-18-2026\/"},"wordCount":296,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/amylyx-pharmaceuticals-to-announce-topline-results-from-its-phase-3-lucidity-clinical-trial-of-avexitide-in-post-bariatric-hypoglycemia-on-august-18-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260817660841r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/amylyx-pharmaceuticals-to-announce-topline-results-from-its-phase-3-lucidity-clinical-trial-of-avexitide-in-post-bariatric-hypoglycemia-on-august-18-2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/amylyx-pharmaceuticals-to-announce-topline-results-from-its-phase-3-lucidity-clinical-trial-of-avexitide-in-post-bariatric-hypoglycemia-on-august-18-2026\/","name":"Amylyx Pharmaceuticals to Announce Topline Results from its Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia on August 18, 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/amylyx-pharmaceuticals-to-announce-topline-results-from-its-phase-3-lucidity-clinical-trial-of-avexitide-in-post-bariatric-hypoglycemia-on-august-18-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/amylyx-pharmaceuticals-to-announce-topline-results-from-its-phase-3-lucidity-clinical-trial-of-avexitide-in-post-bariatric-hypoglycemia-on-august-18-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260817660841r1&sid=flmnd&distro=nx&lang=en","datePublished":"2026-08-17T20:04:12+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/amylyx-pharmaceuticals-to-announce-topline-results-from-its-phase-3-lucidity-clinical-trial-of-avexitide-in-post-bariatric-hypoglycemia-on-august-18-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/amylyx-pharmaceuticals-to-announce-topline-results-from-its-phase-3-lucidity-clinical-trial-of-avexitide-in-post-bariatric-hypoglycemia-on-august-18-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/amylyx-pharmaceuticals-to-announce-topline-results-from-its-phase-3-lucidity-clinical-trial-of-avexitide-in-post-bariatric-hypoglycemia-on-august-18-2026\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260817660841r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260817660841r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/amylyx-pharmaceuticals-to-announce-topline-results-from-its-phase-3-lucidity-clinical-trial-of-avexitide-in-post-bariatric-hypoglycemia-on-august-18-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Amylyx Pharmaceuticals to Announce Topline Results from its Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia on August 18, 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/996169","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=996169"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/996169\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=996169"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=996169"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=996169"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}